Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Lupin to market Eli Lilly's insulin analog product in India

The Mumbai-based pharma company will market and sell Eglucent, a new brand of Lilly's insulin analog Lispro, while Eli Lilly will be responsible for manufacturing and import

BS B2B Bureau  |  Mumbai 

Lupin to market Eli Lilly's insulin analog product in India

and have expanded partnership in India with the Mumbai-based pharma company launching drug Eglucent, a new brand of Lilly’s rapid-acting analog Lispro, in the country.

As per the agreement, will market and sell through its own specialty field force while will be responsible for manufacturing and import. Lilly will continue to sell under the brand name Humalog through its existing channels. had earlier collaborated with Lilly (July 2011) to promote and distribute Lilly’s range of products in India and Nepal.

“We have been very pleased with our partnership with and are happy to see it grow with the launch of Eglucent. The intent of this launch, which is the first for Lilly in the entire emerging markets region, is to increase the reach of analog to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India,” said Edgard Olaizola, managing director, Lilly India.

is indicated for the treatment of patients with mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. will be available in the Indian market in both, the cartridge and disposable pen form. 

is the fifth largest company in the anti-segment with a market share of 6.34 percent growing at 18 percent, according to IMS MAT September 2016. The company also has the distinction of being the only company in the Anti-market with a contemporary portfolio comprising of oral anti-drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16 percent to its India formulations sales (FY 2016).

The Indian market is valued at Rs 9,272 crore and is growing at 19 percent, according to IMS MAT September 2016. The total market is valued at Rs 2,207 crore, out of which the analogue market size is valued at Rs 1,106 crore with a 3 year CAGR of 28 percent. The total molecule market size is Rs 142 crore with a 3 year CAGR of 24 percent, as per the IMS MAT September 2016.

Shakti Chakraborty, group president, India Region Formulations, Lupin, added, “We are excited about expanding our partnership with with the launch of and the progress that we together have made to combat the rising incidence of in India. Our entry into the rapid-acting analog segment will not only bolster our existing portfolio but will also go a long way in strengthening our position in the Indian market.”

RECOMMENDED FOR YOU

Lupin to market Eli Lilly's insulin analog product in India

The Mumbai-based pharma company will market and sell Eglucent, a new brand of Lilly's insulin analog Lispro, while Eli Lilly will be responsible for manufacturing and import

The Mumbai-based pharma company will market and sell Eglucent, a new brand of Lilly's insulin analog Lispro, while Eli Lilly will be responsible for manufacturing and import
and have expanded partnership in India with the Mumbai-based pharma company launching drug Eglucent, a new brand of Lilly’s rapid-acting analog Lispro, in the country.

As per the agreement, will market and sell through its own specialty field force while will be responsible for manufacturing and import. Lilly will continue to sell under the brand name Humalog through its existing channels. had earlier collaborated with Lilly (July 2011) to promote and distribute Lilly’s range of products in India and Nepal.

“We have been very pleased with our partnership with and are happy to see it grow with the launch of Eglucent. The intent of this launch, which is the first for Lilly in the entire emerging markets region, is to increase the reach of analog to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India,” said Edgard Olaizola, managing director, Lilly India.

is indicated for the treatment of patients with mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. will be available in the Indian market in both, the cartridge and disposable pen form. 

is the fifth largest company in the anti-segment with a market share of 6.34 percent growing at 18 percent, according to IMS MAT September 2016. The company also has the distinction of being the only company in the Anti-market with a contemporary portfolio comprising of oral anti-drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16 percent to its India formulations sales (FY 2016).

The Indian market is valued at Rs 9,272 crore and is growing at 19 percent, according to IMS MAT September 2016. The total market is valued at Rs 2,207 crore, out of which the analogue market size is valued at Rs 1,106 crore with a 3 year CAGR of 28 percent. The total molecule market size is Rs 142 crore with a 3 year CAGR of 24 percent, as per the IMS MAT September 2016.

Shakti Chakraborty, group president, India Region Formulations, Lupin, added, “We are excited about expanding our partnership with with the launch of and the progress that we together have made to combat the rising incidence of in India. Our entry into the rapid-acting analog segment will not only bolster our existing portfolio but will also go a long way in strengthening our position in the Indian market.”
image
Business Standard
177 22

Lupin to market Eli Lilly's insulin analog product in India

The Mumbai-based pharma company will market and sell Eglucent, a new brand of Lilly's insulin analog Lispro, while Eli Lilly will be responsible for manufacturing and import

and have expanded partnership in India with the Mumbai-based pharma company launching drug Eglucent, a new brand of Lilly’s rapid-acting analog Lispro, in the country.

As per the agreement, will market and sell through its own specialty field force while will be responsible for manufacturing and import. Lilly will continue to sell under the brand name Humalog through its existing channels. had earlier collaborated with Lilly (July 2011) to promote and distribute Lilly’s range of products in India and Nepal.

“We have been very pleased with our partnership with and are happy to see it grow with the launch of Eglucent. The intent of this launch, which is the first for Lilly in the entire emerging markets region, is to increase the reach of analog to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India,” said Edgard Olaizola, managing director, Lilly India.

is indicated for the treatment of patients with mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. will be available in the Indian market in both, the cartridge and disposable pen form. 

is the fifth largest company in the anti-segment with a market share of 6.34 percent growing at 18 percent, according to IMS MAT September 2016. The company also has the distinction of being the only company in the Anti-market with a contemporary portfolio comprising of oral anti-drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16 percent to its India formulations sales (FY 2016).

The Indian market is valued at Rs 9,272 crore and is growing at 19 percent, according to IMS MAT September 2016. The total market is valued at Rs 2,207 crore, out of which the analogue market size is valued at Rs 1,106 crore with a 3 year CAGR of 28 percent. The total molecule market size is Rs 142 crore with a 3 year CAGR of 24 percent, as per the IMS MAT September 2016.

Shakti Chakraborty, group president, India Region Formulations, Lupin, added, “We are excited about expanding our partnership with with the launch of and the progress that we together have made to combat the rising incidence of in India. Our entry into the rapid-acting analog segment will not only bolster our existing portfolio but will also go a long way in strengthening our position in the Indian market.”

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard